Sellas Life Ownership
| SLS Stock | USD 1.26 0.01 0.80% |
Shares in Circulation | First Issued 2006-12-31 | Previous Quarter 44.8 M | Current Value 57.6 M | Avarage Shares Outstanding 5.6 M | Quarterly Volatility 11.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Sellas |
Sellas Stock Ownership Analysis
The company recorded a loss per share of 0.9. Sellas Life Sciences last dividend was issued on the 8th of November 2019. The entity had 1:50 split on the 8th of November 2019. SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company was founded in 2012 and is headquartered in New York, New York. Sellas Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. To find out more about Sellas Life Sciences contact the company at 646 200 5278 or learn more at https://www.sellaslifesciences.com.Besides selling stocks to institutional investors, Sellas Life also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Sellas Life's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Sellas Life's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Sellas Life Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Sellas Life Sciences are currently held by insiders. Unlike Sellas Life's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Sellas Life's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Sellas Life's insider trades
Sellas Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sellas Life is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sellas Life Sciences backward and forwards among themselves. Sellas Life's institutional investor refers to the entity that pools money to purchase Sellas Life's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Lpl Financial Corp | 2024-06-30 | 51.9 K | Mariner Wealth Advisors, Llc | 2024-06-30 | 44.9 K | Renaissance Technologies Corp | 2024-06-30 | 32.4 K | Jane Street Group, Llc | 2024-06-30 | 28 K | Charles Schwab Investment Management Inc | 2024-06-30 | 16.2 K | Commonwealth Equity Services Inc | 2024-06-30 | 15.6 K | Wedbush Morgan Securities Inc | 2024-06-30 | 15 K | Tower Research Capital Llc | 2024-06-30 | 13.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 3.3 K | Vanguard Group Inc | 2024-06-30 | 1.8 M | Geode Capital Management, Llc | 2024-06-30 | 517 K |
Sellas Life Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sellas Life insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sellas Life's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sellas Life insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kalin Katherine Bach over three months ago Acquisition by Kalin Katherine Bach of 19000 shares of Sellas Life subject to Rule 16b-3 | ||
Cicic Dragan over three months ago Disposition of 35000 shares by Cicic Dragan of Sellas Life at 1.89 subject to Rule 16b-3 | ||
Cicic Dragan over three months ago Disposition of 65000 shares by Cicic Dragan of Sellas Life at 0.5195 subject to Rule 16b-3 | ||
Jane Wasman over six months ago Acquisition by Jane Wasman of 25000 shares of Sellas Life at 1.38 subject to Rule 16b-3 | ||
Angelos Stergiou over six months ago Acquisition or disposition of Sellas Life securities by Angelos Stergiou | ||
Angelos Stergiou over six months ago Acquisition by Angelos Stergiou of 70000 shares of Sellas Life subject to Rule 16b-3 | ||
Angelos Stergiou over a year ago Acquisition by Angelos Stergiou of 450135 shares of Sellas Life subject to Rule 16b-3 | ||
Angelos Stergiou over a year ago Acquisition by Angelos Stergiou of 58000 shares of Sellas Life subject to Rule 16b-3 |
Sellas Life Outstanding Bonds
Sellas Life issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sellas Life Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sellas bonds can be classified according to their maturity, which is the date when Sellas Life Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sellas Stock Analysis
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.